Lopap: A non-inflammatory and cytoprotective molecule in neutrophils and endothelial cells

Autor(es)

Waismam, Kaline ^[1] ; Chudzinski-Tavassi, Ana Marisa ^[2] ; Carrijo-Carvalho, Linda C. ^[2] ; Fernandes Pacheco, Mario T. ^[1] ; Farsky, Sandra H. P. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Clin & Toxicol Anal, Fac Pharmaceut Sci, BR-05503900 Sao Paulo - Brazil

^[2] Butantan Inst, Biochem & Biophys Lab, BR-05503900 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Toxicon; v. 53, n. 6, p. 652-659, MAY 2009.
• Citações Web of Science: 7

Resumo

Lopap (Lonomia obliqua prothrombin activator protease) is a member of the lipocalin family isolated from the extract of L obliqua bristles. Lopap displays serine protease-like activities, including coagulation disturbance, cytokine secretion and antiapoptotic activity in human cultured endothelial cells. Here, we have investigated the effects of the recombinant protein (rLopap) on the inflammatory and apoptotic processes of neutrophils and endothelial cells from male Wistar rats. We found that rLopap did not induce in vivo leukocyte-endothelial interactions in the microvasculature, initial steps of leukocyte recruitment during inflammation. Incubation of rLopap with neutrophils or endothelial cells prevented apoptosis evoked by serum deprivation and induced nitric oxide (NO) production in both cell types, and increased the expression of ICAM-1 by endothelial cells. Simultaneous incubation of endothelial cells or neutrophils with rLopap and N(omega)-nitro-L-arginine methyl ester (L-NAME), a non-specific inhibitor of NO synthases, inhibited NO production and impaired the protection on apoptosis. Differently, incubation of endothelial cells with monoclonal antibody anti ICAM-1 did not change the protection on apoptosis evoked by rLopap. Together, these results indicate that rLopap does not display inflammatory properties in vivo but inhibits apoptosis of neutrophils and endothelial cells depending, at least in part, on NO production. (C) 2009 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 05/59739-9 - Avaliação da atividade in vivo e in vitro do Lopap recombinante, uma proteína ativadora de protrombina da taturana Lonomia obliqua
• Beneficiário: Linda Christian Carrijo Carvalho
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 06/58643-0 - Acao do lopap (lonomia obliqua prothrombin activator protease) sobre os vasos da microcirculacao.
• Beneficiário: Kaline Waismam
• Modalidade de apoio: Bolsas no Brasil - Mestrado